These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39225256)

  • 1. Successful utilization of topical trametinib for neurofibromatosis type I-associated plexiform neurofibroma.
    Melnikov L; Brichta L; Schloemer NJ
    Pediatr Dermatol; 2024; 41(6):1246-1247. PubMed ID: 39225256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
    Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
    Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
    Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
    Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.
    Toledano H; Dotan G; Friedland R; Cohen R; Yassur I; Toledano-Alhadef H; Constantini S; Rootman MS
    Childs Nerv Syst; 2021 Jun; 37(6):1909-1915. PubMed ID: 33751171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of trametinib on the neuropsychological profile of NF1 patients.
    Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
    J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
    Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
    Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
    Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
    J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Trametinib in Neurofibromatosis Type 1-Associated Gastrointestinal Stromal Tumors: A Case Report.
    Fukuda M; Mukohara T; Kuwata T; Sunami K; Naito Y
    JCO Precis Oncol; 2024 Aug; 8():e2300649. PubMed ID: 39116355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1.
    Mateos ME; López-Laso E; Vicente J; Ortega R; Vázquez F; Pérez-Navero JL
    Pediatr Int; 2020 Jul; 62(7):857-859. PubMed ID: 32027426
    [No Abstract]   [Full Text] [Related]  

  • 13. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
    Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I.
    Malhotra N; Levy JMS; Fiorillo L
    Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I.
    Pillay-Smiley N; Fletcher JS; de Blank P; Ratner N
    Pediatr Clin North Am; 2023 Oct; 70(5):937-950. PubMed ID: 37704352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
    Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
    Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
    Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
    Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Trametinib-Associated Folliculitis Eruption With Fluconazole.
    Steele C; Gershon T; Burkhart C; Googe P
    JAMA Dermatol; 2020 Jun; 156(6):706-708. PubMed ID: 32267472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.